Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
Peroxisome proliferator-activated receptor (PPAR)-gamma controls growth, differentiation, and inflammation. PPAR-gamma agonists exert anti-inflammatory effects in vitro and inhibit the activation of pancreas stellate cells, implicated in the formation and progression of fibrosis. We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis. Mice received six hourly intraperitoneal injections with 50 microg/kg of cerulein or saline, three times a week for 6 weeks. One week after the last injection all mice were sacrificed. Untreated mice were compared with mice treated with troglitazone either during weeks 1 to 6 or weeks 4 to 6. All mice that received cerulein injections displayed histopathological signs of chronic pancreatitis at week 7. Troglitazone treatment improved all markers for severity of pancreatitis. Moreover, early and postponed troglitazone treatments were equally effective in diminishing intrapancreatic fibrosis as quantified by Sirius red staining, hydroxyproline content, and laminin staining as well as the increased number of pancreatic stellate cells and pancreas levels of transforming growth factor-beta. Thus, troglitazone attenuated pancreatic damage and inflammation in experimental chronic pancreatitis and remained beneficial in a therapeutic setting when given after initial damage had been established.
van Westerloo
David J
DJ
Laboratory of Experimental Internal Medicine, University of Amsterdam, Amsterdam, The Netherlands. d.j.vanwesterloo@amc.uva.nl
Florquin
Sandrine
S
de Boer
Anita M
AM
Daalhuisen
Joost
J
de Vos
Alex F
AF
Bruno
Marco J
MJ
van der Poll
Tom
T
D000199:Actins / Q000378:metabolism; D000818:Animals; D002454:Cell Differentiation; D002108:Ceruletide / Q000494:pharmacology; D002839:Chromans / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D003094:Collagen / Q000378:metabolism; D004195:Disease Models, Animal; D005355:Fibrosis; D007249:Inflammation; D015850:Interleukin-6 / Q000097:blood; D008024:Ligands; D051379:Mice; D008810:Mice, Inbred C57BL; D009130:Muscle, Smooth / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism; D010195:Pancreatitis / Q000188:drug therapy* / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000378:metabolism; D012965:Sodium Chloride / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000378:metabolism; D053773:Transforming Growth Factor beta1; D000077288:Troglitazone
D000199:Actins; D002839:Chromans; D015850:Interleukin-6; D008024:Ligands; D047495:PPAR gamma; D010975:Platelet Aggregation Inhibitors; D047888:Receptors, Tumor Necrosis Factor, Type I; C508961:Tgfb1 protein, mouse; D045162:Thiazolidinediones; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D012965:Sodium Chloride; D002108:Ceruletide; D003094:Collagen; D000077288:Troglitazone
Am J Pathol. 1999 Nov;155(5):1749-58
10550331
Arch Biochem Biophys. 1961 May;93:440-7
13786180
Lab Invest. 2000 Jan;80(1):47-55
10653002
Baillieres Best Pract Res Clin Gastroenterol. 1999 Jul;13(2):265-89
11030606
Gastroenterology. 2001 Feb;120(3):682-707
11179244
Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G974-8
11292607
Kidney Int. 2001 May;59(5):1899-910
11318962
Toxicol Pathol. 2001 Mar-Apr;29(2):224-31
11421489
Gastroenterology. 2001 Sep;121(3):685-98
11522753
J Biol Chem. 2001 Dec 7;276(49):45888-94
11590167
J Biol Chem. 2002 Jan 4;277(1):141-7
11606585
Biochem Biophys Res Commun. 2002 Feb 15;291(1):55-61
11829461
Pancreas. 2002 Mar;24(2):184-90
11854624
Gastroenterology. 2002 May;122(5):1303-13
11984517
Gastroenterology. 2002 May;122(5):1525-8
11984538
Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1105-12
12016137
Gastroenterology. 2002 Jun;122(7):1924-40
12055599
Curr Opin Clin Nutr Metab Care. 2002 Sep;5(5):551-9
12172480
Ann Med. 2002;34(3):217-24
12173692
Int Immunopharmacol. 2002 Jul;2(8):1029-44
12349941
Adv Drug Deliv Rev. 2002 Nov 5;54(9):1173-97
12393300
Gastrointest Endosc. 2002 Dec;56(6 Suppl):S226-30
12447272
Am J Respir Crit Care Med. 2003 Jan 15;167(2):171-9
12406830
Gastroenterology. 2003 Feb;124(2):361-7
12557142
Pancreas. 2003 Apr;26(3):239-42
12657949
Gastroenterology. 2003 Apr;124(4):1010-9
12671898
Pancreas. 2003 Jul;27(1):58-66
12826907
Intensive Care Med. 2004 May;30(5):951-6
14985957
Crit Care Med. 2004 Oct;32(10):1997-2001
15483406
Lab Invest. 1993 Mar;68(3):296-307
8383778
Bone Miner. 1994 Nov;27(2):133-44
7711521
Gastroenterology. 1995 Jun;108(6):1873-81
7768393
Am J Pathol. 1995 Jul;147(1):42-52
7604884
Br J Surg. 1996 Mar;83(3):349-53
8665189
J Mol Cell Cardiol. 1997 Jan;29(1):247-53
9040039
Nature. 1998 Jan 1;391(6662):79-82
9422508
Gastroenterology. 1998 Aug;115(2):421-32
9679048
Inflamm Bowel Dis. 1998 Aug;4(3):187-95
9741020
Gut. 1999 Aug;45(2):269-77
10403741
Am J Pathol. 1999 Oct;155(4):1087-95
10514391
Hepatogastroenterology. 1999 Sep-Oct;46(29):2751-6
10576340